KLRK1 As a Prognostic Biomarker for Lung Adenocarcinoma Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2022 Feb 8

PMID 35132098

Authors

Yanan Zhang

Zeyang Chen

Aifang Jiang

Guanqi Gao

Affiliations

Soon will be listed here.

Abstract

Lung cancer is one of the most common malignancy worldwide and causes estimated 1.6 million deaths each year. Cancer immunosurveillance has been found to play an important role in lung cancer and may be related with its prognosis. KLRK1, encoding NKG2D, is a homodimeric lectin-like receptor. However, there has not been one research of KLRK1 as a biomarker in lung cancer. Data including patients` clinical characteristics and RNAseq information of KLRK1 from TCGA were downloaded. A total of 1019 patients with lung cancer were included in this study, among which 407 patients were female and 611 patients were male. Evaluations of mRNA expression, diagnostic value by ROC (receiver operating characteristic) curves and prognostic value by survival curve, Cox model and subgroup analysis were performed. The level of KLRK1 expression in lung adenocarcinoma cancer tissues and normal lung tissues was detected by qRT-PCR. The CCK-8 assay investigated the proliferation rate and the wound healing assay assessed the migratory ability in vitro. The expression of KLRK1 in tumor was lower than that in normal tissue. KLRK1 expression was associated with gender, histologic grade, stage, T classification and vital status. Patients with high KLRK1 expression presented an improved overall survival (P = 0.0036) and relapse free survival (P = 0.0031). KLRK1 was found to have significant prognostic value in lung adenocarcinoma (P = 0.015), stage I/II (P = 0.03), older patients (P = 0.0052), and male (P = 0.0047) by subgroup overall survival analysis, and in lung adenocarcinoma (P = 0.0094), stage I/II (P = 0.0076), older patients (P = 0.0072), and male (P = 0.0033) by subgroup relapse free survival analysis. Lung adenocarcinoma cancer patients with high KLRK1 expression presented an improved overall survival (P = 0.015) and relapse free survival (P = 0.0094). In vitro studies indicated that KLRK1 inhibited tumor cell proliferation and migration. KLRK1 was an independent prognostic factor and high KLRK1 expression indicated a better overall and relapse free survival. KLRK1 may be a prognostic biomarker for lung adenocarcinoma cancer.

Citing Articles

Exploring the role of neutrophil extracellular traps in neuroblastoma: identification of molecular subtypes and prognostic implications.

Qi C, Zhao Z, Chen L, Wang L, Zhou Y, Duan G Front Oncol. 2024; 14:1361871.

PMID: 39575432 PMC: 11578966. DOI: 10.3389/fonc.2024.1361871.

Comprehensive time-course gene expression evaluation of high-risk beef cattle to establish immunological characteristics associated with undifferentiated bovine respiratory disease.

Scott M, Valeris-Chacin R, Thompson A, Woolums A, Karisch B Front Immunol. 2024; 15:1412766.

PMID: 39346910 PMC: 11427276. DOI: 10.3389/fimmu.2024.1412766.

The role of KLRG1: a novel biomarker and new therapeutic target.

Zhang Y, Chen S, Tang X, Peng Y, Jiang T, Zhang X Cell Commun Signal. 2024; 22(1):337.

PMID: 38898461 PMC: 11186184. DOI: 10.1186/s12964-024-01714-7.

The effects of the prognostic biomarker SAAL1 on cancer growth and its association with the immune microenvironment in lung adenocarcinoma.

Tong S, Jiang N, Wan J, Chen C, Wang S, Wu C BMC Cancer. 2023; 23(1):275.

PMID: 36973678 PMC: 10041717. DOI: 10.1186/s12885-023-10741-5.

Integrating the Epigenome and Transcriptome of Hepatocellular Carcinoma to Identify Systematic Enhancer Aberrations and Establish an Aberrant Enhancer-Related Prognostic Signature.

Huang P, Zhang B, Zhao J, Li M Front Cell Dev Biol. 2022; 10:827657.

PMID: 35300417 PMC: 8921559. DOI: 10.3389/fcell.2022.827657.

References

Yang D, Sun B, Dai H, Li W, Shi L, Zhang P . T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells. J Immunother Cancer. 2019; 7(1):171. PMC: 6617951. DOI: 10.1186/s40425-019-0642-9. View

Jiang N, Meng X, Mi H, Chi Y, Li S, Jin Z . Circulating lncRNA XLOC_009167 serves as a diagnostic biomarker to predict lung cancer. Clin Chim Acta. 2018; 486:26-33. DOI: 10.1016/j.cca.2018.07.026. View

Jiao Y, Fu Z, Li Y, Zhang W, Liu Y . Aberrant FAM64A mRNA expression is an independent predictor of poor survival in pancreatic cancer. PLoS One. 2019; 14(1):e0211291. PMC: 6351057. DOI: 10.1371/journal.pone.0211291. View

Tang T, Yang C, Brown H, Huang J . Circulating Heat Shock Protein 70 Is a Novel Biomarker for Early Diagnosis of Lung Cancer. Dis Markers. 2018; 2018:6184162. PMC: 6136573. DOI: 10.1155/2018/6184162. View

Schmiedel D, Mandelboim O . NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy. Front Immunol. 2018; 9:2040. PMC: 6141707. DOI: 10.3389/fimmu.2018.02040. View

Paczulla A, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Wang H . Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature. 2019; 572(7768):254-259. PMC: 6934414. DOI: 10.1038/s41586-019-1410-1. View

Duan S, Guo W, Xu Z, He Y, Liang C, Mo Y . Natural killer group 2D receptor and its ligands in cancer immune escape. Mol Cancer. 2019; 18(1):29. PMC: 6391774. DOI: 10.1186/s12943-019-0956-8. View

Jiang Z, Wang M, Xu J . Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer. Life Sci. 2017; 194:1-6. DOI: 10.1016/j.lfs.2017.12.020. View

Jiao Y, Li Y, Ji B, Cai H, Liu Y . Clinical Value of lncRNA LUCAT1 Expression in Liver Cancer and its Potential Pathways. J Gastrointestin Liver Dis. 2019; 28(4):439-447. DOI: 10.15403/jgld-356. View

10.

Lanier L . Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008; 9(5):495-502. PMC: 2669298. DOI: 10.1038/ni1581. View

11.

Grunnet M, Sorensen J . Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2011; 76(2):138-43. DOI: 10.1016/j.lungcan.2011.11.012. View

12.

Li Y, Jiao Y, Li Y, Liu Y . Expression of La Ribonucleoprotein Domain Family Member 4B (LARP4B) in Liver Cancer and Their Clinical and Prognostic Significance. Dis Markers. 2019; 2019:1569049. PMC: 6854232. DOI: 10.1155/2019/1569049. View

13.

Lazarova M, Steinle A . The NKG2D axis: an emerging target in cancer immunotherapy. Expert Opin Ther Targets. 2019; 23(4):281-294. DOI: 10.1080/14728222.2019.1580693. View

14.

Shi L, Li K, Guo Y, Banerjee A, Wang Q, Lorenz U . Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer. Proc Natl Acad Sci U S A. 2018; 115(46):11808-11813. PMC: 6243255. DOI: 10.1073/pnas.1804931115. View

15.

Neal J, Gainor J, Shaw A . Developing biomarker-specific end points in lung cancer clinical trials. Nat Rev Clin Oncol. 2014; 12(3):135-46. DOI: 10.1038/nrclinonc.2014.222. View

16.

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

17.

Fu Z, Jiao Y, Li Y, Ke J, Xu Y, Jia B . PES1 In Liver Cancer: A Prognostic Biomarker With Tumorigenic Roles. Cancer Manag Res. 2019; 11:9641-9653. PMC: 6861535. DOI: 10.2147/CMAR.S226471. View

18.

Zhang X, Cui Y, He M, Jiao Y, Yang Z . Lipocalin-1 Expression as a Prognosticator Marker of Survival in Breast Cancer Patients. Breast Care (Basel). 2020; 15(3):272-280. PMC: 7383281. DOI: 10.1159/000503168. View

19.

Cosman D, Mullberg J, SUTHERLAND C, Chin W, Armitage R, Fanslow W . ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001; 14(2):123-33. DOI: 10.1016/s1074-7613(01)00095-4. View

20.

Yan F, Shen N, Pang J, Zhao N, Deng B, Li B . A regulatory circuit composed of DNA methyltransferases and receptor tyrosine kinases controls lung cancer cell aggressiveness. Oncogene. 2017; 36(50):6919-6928. PMC: 5730463. DOI: 10.1038/onc.2017.305. View